NEW YORK, Jan. 28, 2015 /PRNewswire/ -- Securities lawyers
at Dunnam & Dunnam are investigating allegations for AMAG
Pharmaceuticals, Inc. shareholders (NASDAQ:AMAG). Concerned AMAG
investors who purchased between December 24,
2012 and January 8, 2015 are
encouraged to contact securities attorney Hamilton Lindley by
clicking here.
The law firm's investigation will focus on potential violations
of the federal securities law. AMAG proposed to the U.S. Food and
Drug Administration ("FDA"), on June 2,
2014, changes to the current U.S. label of Feraheme
Injection based on a review of global post-marketing data.
The proposed label changes in the U.S. were to enhance patient
safety by strengthening the warnings and precautions section of the
label, and mitigate the risk of serious hypersensitivity reactions,
including anaphylaxis. The proposed changes were subject to review
and approval by the FDA. On January 7,
2015, after considering AMAG's June
2014 submission and other information, the FDA notified AMAG
that it believes new safety information should be included in the
labeling of Feraheme, including, among other things, a boxed
warning to highlight the risks of serious
hypersensitivity/anaphylaxis reactions and revisions that Feraheme
should only be administered through an intravenous ("IV") infusion,
(i.e., not by IV injection), and should be contraindicated for
patients with any known history of drug allergy. The FDA's
recommended label changes go beyond what AMAG proposed in
June 2014. On this news, AMAG's
shares are down $2.65 (5.67%),
currently trading at $43.33. Our
potential shareholder lawsuit will seek to ensure that AMAG
Pharmaceuticals, Inc. works to enrich shareholders, not just the
management.
Dunnam & Dunnam has significant experience representing
shareholders in securities lawsuits nationwide. AMAG stockholders –
or anyone with knowledge about this situation – should contact
lawyer Hamilton Lindley at hlindley@dunnamlaw.com with questions,
toll free at (844) 702-2990 or visit
http://www.dunnamlaw.com/AMAG.
Dunnam & Dunnam also engages in business litigation and
personal injury law.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/amag-pharmaceuticals-inc-investors-encouraged-to-contact-securities-law-firm-about-investigation-into-allegations-of-corporate-wrongdoing-300027176.html
SOURCE Dunnam & Dunnam